Drug combo for B-cell leukemia that returned after transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a drug called InO, sometimes given with donor immune cells, for people whose B-cell acute lymphoblastic leukemia or lymphoma came back after a prior stem cell transplant. The goal is to see if it works and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 65 years old.
- You have B-cell acute lymphoblastic leukemia or lymphoma that is CD22-positive (a protein on the cancer cells).
- You had a stem cell transplant from a related or unrelated donor, and the cancer came back afterward.
- You are not currently having severe graft-versus-host disease (GvHD), liver GvHD, or a history of liver vein blockage.
- Your kidneys work well enough (creatinine clearance at least 50 mL/min).
- Your liver function is mostly normal (ALT and AST no more than 3 times normal, bilirubin no more than 2 times normal).
- Your heart pumps at least 50% of blood out each beat (echocardiogram).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
This trial tests a full course of immunotherapy (drugs that help your immune system fight cancer) instead of intensive chemotherapy for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older or cannot tolerate strong chemo. It aims to offer an effective, less toxic option.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
This trial tests whether a low dose of a targeted drug called inotuzumab ozogamicin, given after a stem cell transplant, can help prevent acute lymphoblastic leukemia from coming back. It is for people who have already had a transplant and are at high risk for relapse.
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
Hear when a new Leukemia, Lymphocytic, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.